Technology Commercialization

$54B U.S. IVD market to grow 2% per year for five years: Kalorama

By Bruce Carlson

Test makers will need to get creative for growth, and they can do so by focusing on a few growth-rich segments, such as point-of-care products and tissue diagnostics

October 11, 2022

SARS-CoV-2 molecular tests highly accurate in Canadian study

By Dexter Johnson

The diagnostic sensitivity of these molecular tests suggests that one negative test result can effectively rule out SARS-CoV-2 infection for most patients, the researchers said.

October 12, 2022

Contract manufacturing market for IVD products to reach $16.1B in 2022: Kalorama

By Bruce Carlson

Evolving trends in IVD contract manufacturing will result in developed economies retaining more than three-fourths of the total global demand.

October 4, 2022

NanoDx, SkyWater launch nano biosensor

By LabPulse.com staff writers

The companies said that as a result of the development, NanoDx is ready to prepare and submit the product for review by the U.S. Food and Drug Administration (FDA) with the aim of eventually commercializing a product based on the technology.

August 25, 2022

Huron Digital taps Audil Virk as president

By LabPulse.com staff writers

Virk has executive leadership and operational experience in general management, strategy, product development, and technology commercialization, Huron said.

April 14, 2022

Babson Diagnostics receives CAP accreditation

By LabPulse.com staff writers

Babson’s lab in Austin first received CAP accreditation in 2020. In the renewal application, the company for the first time demonstrated proficiency for its proprietary testing techniques, which  run broad blood panels using one-tenth the sample volume of traditional blood tests. The company has developed miniaturized assays to optimize each microsample.

March 17, 2022

Lucence, Waseda University partner on liquid biopsy test

By LabPulse.com staff writers

Lucence believes the technology could be used in potential applications in early cancer detection and disease monitoring. Lucence plans to commercialize the liquid biopsy platform from its CLIA-licensed laboratory in Palo Alto.

March 23, 2021

Page 1 of 1